IPP Bureau
FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL
By IPP Bureau - February 23, 2026
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
CARE Hospitals positions workforce health as a strategic business imperative at HR Conclave 2026
By IPP Bureau - February 23, 2026
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar
By IPP Bureau - February 23, 2026
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
Surya Brasil eyes India expansion after 30% US growth
By IPP Bureau - February 23, 2026
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
PharmEasy integrates with Samsung Health to streamline digital healthcare
By IPP Bureau - February 23, 2026
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
BioVersys’ novel TB drug shows promising results in Phase 2a Trial
By IPP Bureau - February 23, 2026
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal
By IPP Bureau - February 23, 2026
Bavarian Nordic bags $22.5M Canadian vaccine order
By IPP Bureau - February 23, 2026
The order will cover the manufacturing of bulk vaccine in 2026
Siegfried delivers strong 2025 performance, bolsters US expansion
By IPP Bureau - February 23, 2026
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
By IPP Bureau - February 23, 2026
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Morepen Labs lands record Rs. 825 crore global CDMO contract
By IPP Bureau - February 23, 2026
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Lupin receives European Commission approval for biosimilar Ranibizumab
By IPP Bureau - February 23, 2026
BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia
By IPP Bureau - February 23, 2026
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Merck restructures Human Health division for future growth
By IPP Bureau - February 23, 2026
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator
By IPP Bureau - February 22, 2026
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
